Citation: Zhiyu Zhang, Wenfei Xu, Zhitong Chen, Xiran He, Xujuan Li, Zishan Huang, Hong Sun, Zhaogang Sun, Hongqian Chu, Wenjing Liu. Dual-stimuli responsive nanoagonist activating the STING and TLR9 pathways for enhanced immunotherapy[J]. Chinese Chemical Letters, ;2026, 37(11): 112911. doi: 10.1016/j.cclet.2026.112911 shu

Dual-stimuli responsive nanoagonist activating the STING and TLR9 pathways for enhanced immunotherapy

Zhiyu Zhang ^{a, 1} ,
Wenfei Xu ^{a, 1} ,
Zhitong Chen ^a ,
Xiran He ^b ,
Xujuan Li ^c ,
Zishan Huang ^a ,
Hong Sun ^a ,
Zhaogang Sun ^{a, *,} ,
Hongqian Chu ^{a, *,} ,
Wenjing Liu ^{a, *,}

a.
Translational Medicine Center, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
b.
Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
c.
Yun’an District Traditional Chinese Medicine Hospital, Yunfu 527500, China

sunzg75@163.com

chq0314@bjmu.edu.cn

liuwenjing@ustc.edu

Received Date: 13 March 2026
Revised Date: 8 May 2026
Accepted Date: 9 May 2026
Available Online: 10 May 2026

Figures(6)

Despite the tremendous progress that immunotherapy has made from a marginal concept to a first-line treatment for cancer, the effective activation of innate immunity remains a challenge. The foremost strategy for effective immune activation focuses on harnessing the adaptive immune response. Currently, stimulator of interferon genes (STING) and Toll-like receptor 9 (TLR9) have emerged as particularly promising targets for bridging innate and adaptive immunity. However, single-agonist therapies targeting TLR9 and STING are inadequate for immune activation due to their limited function and susceptibility to the compensatory mechanisms of the tumor microenvironment (TME), and are accompanied by off-target effects, which limit their wide clinical application. Here, we demonstrate a dual-stimuli-responsive nanoagonist named ZIF@AC by integration of acid-degradable zeolitic imidazolate framework-8 (ZIF-8) and adenosine 5′-triphosphate (ATP)-activatable CpG oligonucleotides (ODNs) for TLR9 and STING co-activation. We found that ZIF@AC not only exhibited a favorable safety profile but also effectively reversed immunosuppression within the TME. This reversal was achieved by increasing the M1-type macrophage ratio, promoting dendritic cell (DC) maturation, and enhancing the secretion of pro-inflammatory factors. Consequently, these changes led to an increase in the infiltration of effector T cells and potentiated the antitumor immune response in vivo, and ultimately resulted in effective tumor suppression. This nanoagonist represents a pivotal advance toward optimally safe and potent cancer immunotherapies.
- Nanoagonist,
- Immunotherapy,
- Tumor microenvironment,
- Toll-like receptor 9 (TLR9),
- Stimulator of interferon genes (STING),
- Metal-organic framework (MOF)
1. [1]
  D.M. Pardoll, Nat. Rev. Cancer 12 (2012) 252–264. doi: 10.1038/nrc3239
2. [2]
  A. Ribas, J.D. Wolchok, Science 359 (2018) 1350–1355. doi: 10.1126/science.aar4060
3. [3]
  M.A. Postow, M.K. Callahan, J.D. Wolchok, J. Clin. Oncol. 33 (2015) 1974–1982. doi: 10.1200/JCO.2014.59.4358
4. [4]
  C. Robert, Nat. Commun. 11 (2020) 3801. doi: 10.1038/s41467-020-17670-y
5. [5]
  M. Tarannum, X. Ding, M. Barisa, et al., Nat. Biotechnol. 43 (2025) 516–533. doi: 10.1038/s41587-025-02629-5
6. [6]
  O. Tsahouridis, M. Xu, F. Song, et al., Nat. Cancer 6 (2025) 1145–1156. doi: 10.1038/s43018-025-01015-z
7. [7]
  A. Fenis, O. Demaria, L. Gauthier, et al., Nat. Rev. Immunol. 24 (2024) 471–486. doi: 10.1038/s41577-023-00982-7
8. [8]
  D. Memon, A.J. Schoenfeld, D. Ye, et al., Cancer Cell 42 (2024) 209–224.e9. doi: 10.1016/j.ccell.2023.12.013
9. [9]
  Q. Sun, Z. Hong, C. Zhang, et al., Signal Transduct. Target Ther. 8 (2023) 320. doi: 10.1038/s41392-023-01522-4
10. [10]
  J. Leinwand, G. Miller, Nat. Immunol. 21 (2020) 1152–1159. doi: 10.1038/s41590-020-0761-y
11. [11]
  K.B. Kennel, F.R. Greten, Nat. Rev. Cancer 25 (2025) 945–964. doi: 10.1038/s41568-025-00872-1
12. [12]
  J.Y. Deng, Q. Gou, L. Yang, et al., J. Immunother. Cancer 11 (2023) e007218. doi: 10.1136/jitc-2023-007218
13. [13]
  K. Aliazis, A. Christofides, R. Shah, et al., Nat. Cancer 6 (2025) 924–937. doi: 10.1038/s43018-025-00986-3
14. [14]
  J. Sawada, Y. Kikuchi, M. Duah, et al., Nat. Immunol. 26 (2025) 1766–1780. doi: 10.1038/s41590-025-02259-8
15. [15]
  W. Yan, Y. Cao, S. Xu, et al., Adv. Mater. 37 (2025) 2411361. doi: 10.1002/adma.202411361
16. [16]
  Y.T. Liu, Y.L. Wang, S. Wang, et al., Mol. Cancer 24 (2025) 254. doi: 10.1049/icp.2025.3057
17. [17]
  M. Ochoa de Olza, B. Navarro Rodrigo, S. Zimmermann, et al., Lancet Oncol. 21 (2020) e419–e430. doi: 10.1016/S1470-2045(20)30234-5
18. [18]
  T. Zhang, W. Yu, X. Cheng, et al., Sci. Immunol. 9 (2024) eadh2334. doi: 10.1126/sciimmunol.adh2334
19. [19]
  X. Wang, Z. Wang, Q. Liao, et al., Nat. Commun. 16 (2025) 3348. doi: 10.1038/s41467-025-58511-0
20. [20]
  C.J. Imianowski, Q. Chen, C.J. Workman, et al., Nat. Rev. Cancer 25 (2025) 703–722. doi: 10.1038/s41568-025-00832-9
21. [21]
  P. Yuan, X. Xu, D. Hu, et al., J. Am. Chem. Soc. 145 (2023) 7941–7951. doi: 10.1021/jacs.2c13218
22. [22]
  J. Xu, L. Ding, J. Mei, et al., Signal Transduct. Target Ther. 10 (2025) 268. doi: 10.3390/land14020268
23. [23]
  S. Joshi, A. Sharabi, Pharmacol. Ther. 235 (2022) 108114. doi: 10.1016/j.pharmthera.2022.108114
24. [24]
  S. He, L. Zheng, C. Qi, Mol. Cancer 24 (2025) 5. doi: 10.1109/cisat66811.2025.11181725
25. [25]
  K.A. Warrick, C.N. Vallez, H.E. Meibers, et al., Annu. Rev. Immunol. 43 (2025) 489–514. doi: 10.1146/annurev-immunol-083122-040624
26. [26]
  A. Iwasaki, R. Medzhitov, Science 327 (2010) 291–295. doi: 10.1126/science.1183021
27. [27]
  A. Iwasaki, R. Medzhitov, Nat. Immunol. 16 (2015) 343–353. doi: 10.1038/ni.3123
28. [28]
  Z. Zhang, C. Zhang, Nat. Rev. Immunol. 25 (2025) 425–444. doi: 10.1038/s41577-024-01112-7
29. [29]
  Z. Lv, X. Guo, R. Zhang, et al., J. Am. Chem. Soc. 147 (2025) 13545–13555. doi: 10.1021/jacs.5c00481
30. [30]
  D. Verthelyi, K.J. Ishii, M. Gursel, et al., J. Immunol. 166 (2001) 2372–2377. doi: 10.4049/jimmunol.166.4.2372
31. [31]
  A.M. Krieg, Nat. Rev. Drug Discov. 5 (2006) 471–484. doi: 10.1038/nrd2059
32. [32]
  B. Temizoz, K. Hioki, S. Kobari, et al., Int. Immunol. 34 (2022) 353–364. doi: 10.1093/intimm/dxac012
33. [33]
  C.K. Tang, T. Aoshi, N. Jounai, et al., PLoS One 8 (2013) e60038. doi: 10.1371/journal.pone.0060038
34. [34]
  Y. Sun, L. Liu, H. He, et al., J. Control. Release 379 (2025) 327–343. doi: 10.1117/12.3085475
35. [35]
  Y. Li, Z. Chen, X. Lu, et al., Nano Res. 16 (2023) 13322–13334. doi: 10.1007/s12274-023-6295-5
36. [36]
  B.R. Kimmel, K. Arora, N.C. Chada, et al., Nat. Biomed. Eng. 9 (2025) 1719–1739. doi: 10.1038/s41551-025-01400-0
37. [37]
  N.S. Hsu, C. Tang, R.V. Mendes, et al., Nat. Chem. 17 (2025) 1941–1951. doi: 10.1038/s41557-025-01930-9
38. [38]
  X. Liu, S. Chen, J. Huang, et al., Nat. Nanotechnol. 19 (2024) 1745–1756. doi: 10.1038/s41565-024-01759-2
39. [39]
  Y. Guo, Q. Bao, P. Hu, et al., Nat. Commun. 14 (2023) 7306. doi: 10.1038/s41467-023-42972-2
40. [40]
  A.J. Grippin, D. Lee, E.E. Parkes, et al., Nat. Cancer 6 (2025) 1311–1325. doi: 10.1038/s43018-025-01025-x
41. [41]
  H. Zhang, C. Liang, X. Ding, et al., Chin. Chem. Lett. 36 (2025) 110525. doi: 10.1016/j.cclet.2024.110525
42. [42]
  L. Xue, A.S. Thatte, D. Mai, et al., Nat. Rev. Mater. 9 (2024) 100–118.
43. [43]
  Y. Sun, L. Zheng, Y. Yang, et al., Nano-Micro Lett. 12 (2020) 103. doi: 10.1007/978-981-15-7056-8_7
44. [44]
  C. He, D. Liu, W. Lin, Chem. Rev. 115 (2015) 11079–11108. doi: 10.1021/acs.chemrev.5b00125
45. [45]
  H. Zheng, Y. Zhang, L. Liu, et al., J. Am. Chem. Soc. 138 (2016) 962–968. doi: 10.1021/jacs.5b11720
46. [46]
  S. Hu, L.L. Yang, C. Yan, et al., Chem. Eng. J. 498 (2024) 154844. doi: 10.1016/j.cej.2024.154844
47. [47]
  B. Liu, W. Xu, W. Xu, et al., Chin. Chem. Lett. 37 (2026) 111851. doi: 10.1016/j.cclet.2025.111851
48. [48]
  B. Ding, H. Chen, J. Tan, et al., Angew. Chem. Int. Ed. 62 (2023) e202215307. doi: 10.1002/anie.202215307
49. [49]
  J. Li, W. Lv, Z. Han, et al., Adv. Sci. 12 (2025) 2501542. doi: 10.1002/advs.202501542
50. [50]
  J. Kim, H.S. Kim, J.H. Chung, Exp. Mol. Med. 55 (2023) 510–519. doi: 10.1038/s12276-023-00965-7
51. [51]
  S. Liang, J. Yao, D. Liu, et al., Chin. Chem. Lett. 36 (2025) 109856. doi: 10.1016/j.cclet.2024.109856
52. [52]
  L. Sun, F. Shen, L. Tian, et al., Adv. Mater. 33 (2021) 2007910. doi: 10.1002/adma.202007910
53. [53]
  J. Yan, G. Wang, L. Xie, et al., Adv. Mater. 34 (2022) 2105783. doi: 10.1002/adma.202105783
54. [54]
  Z. Ding, R. Wang, Y. Li, et al., Mol. Cell 85 (2025) 2610–2625.e5. doi: 10.1016/j.molcel.2025.06.005
55. [55]
  C. Deng, J. Zhang, Y. Yang, et al., Small 21 (2025) e2503117. doi: 10.1002/smll.202503117
1. [1]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
2. [2]
  Kaiyue Yang , Yifan Zhang , Shamei Luo , Chenxi Yu , Lin Chen , Qingyu Yu , Chenlu Huang , Guilei Ma , Linhua Zhang , Dunwan Zhu . Multifunctional nanoadjuvants-aided synergistic photothermal-immunotherapy of tumor. Chinese Chemical Letters, 2026, 37(4): 112324-. doi: 10.1016/j.cclet.2025.112324
3. [3]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
4. [4]
  Lei Cao , Weidong Huang , Longlin Yin , Yu Liang , Wenhao Li , Congrui Liu , Ping Xie , Zhaonan Li , Tao Lu , Xueqin Huang , Shi Zhou , Wencheng Wu . Nanotechnology-driven innovations in transarterial chemoembolization for hepatocellular carcinoma: A focus on smart and flexible platforms. Chinese Chemical Letters, 2026, 37(8): 112643-. doi: 10.1016/j.cclet.2026.112643
5. [5]
  Xue Ma , Anning Li , Zhiliang Gao , Ning Wang , Mengqi Li , Kanaparedu P.C. Sekhar , Muthupandian Ashokkumar , Shumei Zhai , Jiwei Cui , Qun Yu . Vaccination of STING agonists-loaded nanoemulsions for cancer immunotherapy. Chinese Chemical Letters, 2026, 37(6): 111410-. doi: 10.1016/j.cclet.2025.111410
6. [6]
  Sameena Noor Khattak , Kodzo Prosper Adzavon , Weijian Zhao , Wang Sheng . Advances in neoantigen peptide-based nanovaccines for targeted tumor immunotherapy: Multifaceted strategies, challenges, and future perspectives. Chinese Chemical Letters, 2026, 37(11): 112244-. doi: 10.1016/j.cclet.2025.112244
7. [7]
  Zhiyuan Huang , Fangqiu Fu , Chaoqiang Deng , Shiyang Wu , Mingxuan Huang , Xianyi Sha , Ming Q Wei , Zhiwen Zhang , Yang Zhang . Strategies of designing lymph nodes-targeting nanoparticles for cancer immunotherapy. Chinese Chemical Letters, 2026, 37(9): 111993-. doi: 10.1016/j.cclet.2025.111993
8. [8]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
9. [9]
  Zhiqiang Cui , Dongxiang Zhang , Yanru Huang , Chunyu Shao , Yiming Zhang , Changliang Sun , Xin-Dong Jiang , Xiaohong Sun , Qinghuan Xiao . Novel 1-phenylethyl-containing aza-BDOIPY for phototherapy and simultaneous monitoring of tumor immune microenvironment reprogramming. Chinese Chemical Letters, 2025, 36(7): 110460-. doi: 10.1016/j.cclet.2024.110460
10. [10]
  Shao-Qi Guan , Chen-Hui Liu , Ya-Ping Wang , Xiao-Dong Zhang , Zhong-Min Cao , Mei Pan . Cancer cell membrane-biomimetic metallacycles for tumor microenvironment-responsive ferroptosis/apoptosis therapy with low systemic toxicity. Chinese Chemical Letters, 2026, 37(7): 111692-. doi: 10.1016/j.cclet.2025.111692
11. [11]
  Guanghui Lin , Jieyao Chen , Xiaojia Liu , Yitong Lin , Xudong Zhu , Guotao Yuan , Bowen Yang , Shuanshuan Guo , Yue Pan , Jianhua Zhou . Sustained modulation of tumor microenvironment via sorafenib-loaded mesoporous ferromanganese nanozymes for enhanced apoptosis-ferroptosis cancer therapy. Chinese Chemical Letters, 2025, 36(8): 111018-. doi: 10.1016/j.cclet.2025.111018
12. [12]
  Meng Sun , Jiazhen Yang , Leijiao Li , Yunhui Li , Wenliang Li , Jianxun Ding . Engineered bacteria potentiate cancer immunotherapy. Chinese Chemical Letters, 2025, 36(9): 111093-. doi: 10.1016/j.cclet.2025.111093
13. [13]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
14. [14]
  Rongrong Zheng , Zuxiao Chen , Qiuyuan Li , Ni Yang , Wenjun Zhang , Chuyu Huang , Linping Zhao , Xin Chen , Hong Cheng , Shiying Li . Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition. Chinese Chemical Letters, 2025, 36(12): 110865-. doi: 10.1016/j.cclet.2025.110865
15. [15]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
16. [16]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
17. [17]
  Donghu Yu , Junneng Wang , Lei Hu , Youxian Wu , Tianqing Wang , Zhiyu Li , Zefen Wang , Qihang Ding , Yao Sun , Zhiqiang Li . Knowledge structures and research hotspots of immunotherapy for brain metastasis, glioma, meningioma, and pituitary adenoma: A bibliometric and visualization review. Chinese Chemical Letters, 2025, 36(12): 110995-. doi: 10.1016/j.cclet.2025.110995
18. [18]
  Xinlu Zhang , Yongxin Liu , Huan Li , Shutong Chen , Guocheng Wang , Xu Zhang , Chen Cao , Xiaoyuan Chen , Sheng Wang . A hypoxia-activated copper ion nanoexchanger for cancer immunotherapy by in situ precise production of immunogenic cell death inducer. Chinese Chemical Letters, 2026, 37(3): 111404-. doi: 10.1016/j.cclet.2025.111404
19. [19]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
20. [20]
  Dongsheng Zhang , Tingting Wang , Cheng-Ao Li , Yi Tang , Fangyang Wang , Qiang Wang , Hongqing Li , Xun Zhang , Duo Sun , Yueying Zhang , Jiang Ming , Xiao Chen , Xiaolan Chen , Jingchao Li , Xinhui Su . Dual-gated delivery of melittin combined with moderate photothermal treatment using NIR-responsive Pd nanosheets for enhanced cancer immunotherapy. Chinese Chemical Letters, 2026, 37(5): 111399-. doi: 10.1016/j.cclet.2025.111399

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(41)
HTML views(4)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142